crypto in dollars Top snippets

Xiong 'an Center of Beijing-Tianjin-Hebei National Technology Innovation Center officially started operation. On December 12th, Xiong 'an Center of Beijing-Tianjin-Hebei National Technology Innovation Center officially started operation, including the cooperation project of Xiong 'an Medical and Industrial Cross Transformation Research Institute of Peking University People's Hospital and the fourth generation semiconductor material doped AlN epitaxial wafer, and many independent innovative projects landed in xiong'an new area. As a national innovation platform, Xiong 'an Center will focus on key tasks such as building a first-class innovation platform, forming a composite innovation team, and improving the innovation and entrepreneurship ecology, and strive to create an important source of independent innovation and original innovation. (CCTV News)Laiyifen set up a business development company including integrated circuit business. The enterprise search APP shows that recently, Shanghai Laiyifen Future Domain Business Development Co., Ltd. was established, with the legal representative of Yu Ruifen and the registered capital of 1 million yuan. Its business scope includes: the second type of value-added telecommunications business; Internet information service; Communication equipment sales; Integrated circuit chips and product sales; Integrated circuit sales, etc. Enterprise investigation shows that the company is wholly owned by Laiyi.Treasury futures rose by 0.30%, the 30-year main contract rose by 0.30%, and the 30-year main contract rose by 0.30%, a record high. The 10-year main contract rose by 0.12%, the 5-year main contract rose by 0.05% and the 2-year main contract rose by 0.02%.

Hang Seng Science and Technology Index rose to 1%, while Kewang shares rose, with Billie Billie (09626.HK) rising by over 4%, Baidu (09888.HK) rising by 2.8%, Aauto Quicker (01024.HK), Tencent Holdings (00700.HK) rising by 1.8% and Alibaba (09988.HK) rising by over 1%.Backbone Technology: The holding subsidiary recently signed a strategic cooperation agreement on intelligent robots. Backbone Technology (002779) said on the interactive platform on December 12 that recently, Jiangsu Jianmi, the holding subsidiary of the company, signed strategic cooperation agreements with Dongsheng Zhilian and Nanjing Ji Rong respectively, working together to develop and apply automation, visualization and intelligent robots, and promoting the application and development of intelligent technologies in a wider range of fields. Jiangsu Jianmi's Lingrui P1 quadruped robot dog can be used for industrial park management, fire control and public security, daily inspection of power grid and electric power, and inspection of special operation scenes such as smelting enterprises and hazardous chemicals.FTSE China A50 index futures rose 1%.

Shibor reported 1.4820% overnight, down 4.6 basis points; In 7 days, shibor reported 1.6350%, down 8.7 basis points; In three months, shibor reported 1.7400%, down 0.4 basis points.Treasury futures rose by 0.30%, the 30-year main contract rose by 0.30%, and the 30-year main contract rose by 0.30%, a record high. The 10-year main contract rose by 0.12%, the 5-year main contract rose by 0.05% and the 2-year main contract rose by 0.02%.The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.